1. Home
  2. TRML vs UIS Comparison

TRML vs UIS Comparison

Compare TRML & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRML
  • UIS
  • Stock Information
  • Founded
  • TRML 2021
  • UIS 1942
  • Country
  • TRML United States
  • UIS United States
  • Employees
  • TRML N/A
  • UIS N/A
  • Industry
  • TRML Biotechnology: Pharmaceutical Preparations
  • UIS EDP Services
  • Sector
  • TRML Health Care
  • UIS Technology
  • Exchange
  • TRML Nasdaq
  • UIS Nasdaq
  • Market Cap
  • TRML 509.8M
  • UIS 474.3M
  • IPO Year
  • TRML N/A
  • UIS N/A
  • Fundamental
  • Price
  • TRML $13.84
  • UIS $4.47
  • Analyst Decision
  • TRML Strong Buy
  • UIS Hold
  • Analyst Count
  • TRML 6
  • UIS 1
  • Target Price
  • TRML $45.20
  • UIS $6.50
  • AVG Volume (30 Days)
  • TRML 360.6K
  • UIS 526.7K
  • Earning Date
  • TRML 03-13-2025
  • UIS 05-06-2025
  • Dividend Yield
  • TRML N/A
  • UIS N/A
  • EPS Growth
  • TRML N/A
  • UIS N/A
  • EPS
  • TRML N/A
  • UIS N/A
  • Revenue
  • TRML N/A
  • UIS $2,008,400,000.00
  • Revenue This Year
  • TRML $363.93
  • UIS N/A
  • Revenue Next Year
  • TRML N/A
  • UIS $3.00
  • P/E Ratio
  • TRML N/A
  • UIS N/A
  • Revenue Growth
  • TRML N/A
  • UIS N/A
  • 52 Week Low
  • TRML $11.87
  • UIS $3.32
  • 52 Week High
  • TRML $29.79
  • UIS $8.93
  • Technical
  • Relative Strength Index (RSI)
  • TRML 37.41
  • UIS 44.45
  • Support Level
  • TRML $16.39
  • UIS $4.08
  • Resistance Level
  • TRML $17.36
  • UIS $4.31
  • Average True Range (ATR)
  • TRML 1.03
  • UIS 0.20
  • MACD
  • TRML -0.35
  • UIS 0.11
  • Stochastic Oscillator
  • TRML 1.72
  • UIS 66.27

About TRML Tourmaline Bio Inc.

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides solutions that transform digital workplaces securely and create exceptional end-user experiences. CA&I provides digital platform, applications and infrastructure solutions. ECS provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments.

Share on Social Networks: